Harrow Health/$HROW
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Harrow Health
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
Ticker
$HROW
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
382
Website
Harrow Health Metrics
BasicAdvanced
$1.2B
-
-$0.61
0.41
-
Price and volume
Market cap
$1.2B
Beta
0.41
52-week high
$56.01
52-week low
$20.85
Average daily volume
427K
Financial strength
Current ratio
0.907
Quick ratio
0.357
Long term debt to equity
215.848
Total debt to equity
410.022
Interest coverage (TTM)
0.20%
Profitability
EBITDA (TTM)
19.375
Gross margin (TTM)
74.53%
Net profit margin (TTM)
-10.19%
Operating margin (TTM)
2.24%
Effective tax rate (TTM)
-0.75%
Revenue per employee (TTM)
$560,000
Management effectiveness
Return on assets (TTM)
0.90%
Return on equity (TTM)
-37.31%
Valuation
Price to revenue (TTM)
5.333
Price to book
20.06
Price to tangible book (TTM)
-8.97
Price to free cash flow (TTM)
-30.944
Free cash flow yield (TTM)
-3.23%
Free cash flow per share (TTM)
-1.026
Growth
Revenue change (TTM)
53.49%
Earnings per share change (TTM)
-34.30%
3-year revenue growth (CAGR)
39.06%
10-year revenue growth (CAGR)
52.06%
3-year earnings per share growth (CAGR)
-8.16%
10-year earnings per share growth (CAGR)
-6.44%
What the Analysts think about Harrow Health
Analyst ratings (Buy, Hold, Sell) for Harrow Health stock.
Bulls say / Bears say
Harrow Health's preliminary Q4 sales are projected between $65 million and $67 million, surpassing analyst estimates of $58.4 million, indicating strong revenue growth. (reuters.com)
Analysts from BTIG Research initiated coverage on Harrow with a 'buy' rating and a $62.00 target price, reflecting confidence in the company's future performance. (defenseworld.net)
Harrow successfully manufactured the first of three commercial-scale batches of Triesence, positioning the company for a 2024 relaunch of this FDA-approved product. (fastbull.com)
In Q3 2023, Harrow reported revenues of $34.3 million, missing the consensus estimate of $37.58 million, and adjusted EPS loss of $(0.09), below the expected $0.04, indicating financial underperformance. (markets.businessinsider.com)
A short report by Bonitas Research alleged undisclosed FDA warnings and a DOJ subpoena related to Harrow's marketing practices, leading to a share price decline of over 7% on February 22, 2023. (marketwirenews.com)
Harrow reduced its FY23 revenue guidance from $135 million-$143 million to $129 million-$136 million, and adjusted EBITDA guidance to $36 million-$41 million, reflecting lowered financial expectations. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Harrow Health Financial Performance
Revenues and expenses
Harrow Health Earnings Performance
Company profitability
Harrow Health News
AllArticlesVideos
Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States
Business Wire·2 weeks ago
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm
Business Wire·4 weeks ago
Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harrow Health stock?
Harrow Health (HROW) has a market cap of $1.2B as of August 01, 2025.
What is the P/E ratio for Harrow Health stock?
The price to earnings (P/E) ratio for Harrow Health (HROW) stock is 0 as of August 01, 2025.
Does Harrow Health stock pay dividends?
No, Harrow Health (HROW) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Harrow Health dividend payment date?
Harrow Health (HROW) stock does not pay dividends to its shareholders.
What is the beta indicator for Harrow Health?
Harrow Health (HROW) has a beta rating of 0.41. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.